ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.
Mitchell R. Smith, Brad S. Kahl(UW Health University Hospital), Kami J. Maddocks(The Ohio State University), Samir Parekh(The Ohio State University Wexner Medical Center), John P. Leonard(New York University), Brian G. Till(University of Washington), Jonathan W. Friedberg(University of Rochester), Peter Martin(Northwestern University), Rachel E. Lerner(Frauenshuh Cancer Center), Mark D. Romer(Good Samaritan Hospital), Paolo F. Caimi(University Hospitals Seidman Cancer Center), Tareq Al Baghdadi(IHA Hematology Oncology Consultants), Carla Casulo(University of Rochester Medical Center), David J. Inwards(Mayo Clinic), Nancy L. Bartlett(Washington University in St. Louis), Lynne I. Wagner(University of North Carolina at Chapel Hill), David T. Yang(University of Wisconsin–Madison), Opeyemi A. Jegede(Dana-Farber Cancer Institute), Richard F. Little(Dana-Farber Cancer Institute), Lale Kostakoglu(Mount Sinai Hospital)
Cited by 19
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k